The successful use of targeted IL‐1β therapy for T2D has been further demonstrated in clinical trials, and Anakinra, an IL‐1β receptor antagonist improved blood glucose levels and islet secretion in patients with T2D after 2 weeks of treatment [58]. The gene discussed is IL1B; the disease is type 2 diabetes mellitus.